Answers are grounded in this paper and cite their sources.
This review highlights diverse diagnostic methods and treatment strategies for castleman disease, indicating critical differences between unicentric and multicentric types.
Marked by clinical and pathological heterogeneity, Castleman disease (CD) is a lymphoproliferative disorder classified into unicentric (UCD) and multicentric (MCD) types. Distinct subtypes of Castleman disease differ in pathogenesis, pathology, and prognosis, yet diagnosis and treatment remain challenging, requiring standardized approaches. This paper explores the classification, pathological characteristics, diagnostic methods, and treatment strategies of CD, with a focus on the clinical and pathological features of different subtypes. Through analysis of recent literature on clinical presentations, imaging, histopathological diagnostic criteria, and therapeutic outcomes, this study provides evidence-based guidance for clinical practice. The results show that CD can be histologically categorized into hyaline vascular (HV), plasmacytic (PC), and mixed variants. Besides, MCD is further subdivided into HHV-8-associated, POEMS syndrome-associated, and idiopathic (iMCD) subtypes. The diagnostic approach combines clinical presentation, imaging results, and pathological evidence while excluding infectious, autoimmune, and malignant disorders. Treatment for UCD primarily involves surgical excision with favorable prognosis, whereas MCD requires tailored regimens including antiviral therapy, immunosuppression, targeted agents, and chemotherapy. Despite their efficacy in achieving quick symptom relief, corticosteroids are predominantly used as ancillary agents due to the constraints imposed by their long-term adverse effects.
No takes yet. Share an insight, caveat, or question.
Kun Cao (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: